Cystic fibrosis transmembrane conductance regulator gene mutations

• US 10,655,179 B2
• Filed: 01/08/2018
• Issued: 05/19/2020
• Est. Priority Date: 08/18/2005
• Status: Active Grant

• Current Assignee: Quest Diagnostics Investments Incorporated (Quest Diagnostics Incorporated)
• Original Assignee: Quest Diagnostics Investments Incorporated (Quest Diagnostics Incorporated)
• Inventors: Hantash, Feras
• Primary Examiner(s): Haney, Amanda
• Application Number:
  US15/864,469
• Publication Number:
  US 20180208987A1
• Time in Patent Office: 862 Days
• Field of Search: None
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/16 Primer sets for multiplex assays
• CPC Class Codes: C12Q 2600/172 Haplotypes

Abstract

The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. The mutations include duplication of exons including duplication of exons 6b through 10. Methods of identifying if an individual contains the exons 6b through 10 duplication are provided as well as nucleic acid fragments that contain the junction site of the duplicated segment. The detection of additional mutations in the CFTR gene are also provided.

Claims

1. A kit comprising:

(i) a forward primer that comprises the sequence of SEQ ID NO;

89; and

(ii) a reverse primer that comprises the sequence of SEQ ID NO;

90,

wherein the forward primer or reverse primer is detectably labeled.

2. The kit of claim 1, further comprising a nucleic acid probe that binds to an amplification product produced by the forward primer and the reverse primer.

3. The kit of claim 2, wherein the nucleic acid probe is detectably labeled.

4. The kit of claim 2, wherein the nucleic acid probe spans a junction site between exons 10 and 6b resulting from a duplication of exon 6b through exon 10 of the CFTR gene.

5. The kit of claim 2, wherein the nucleic acid probe spans a IVS10+2,987/IVS6a+415 junction site.

6. The kit of claim 2, wherein the nucleic acid probe comprises the sequence of SEQ ID NO:

2.

7. The kit of claim 2, wherein the nucleic acid probe comprises the sequence of SEQ ID NO:

3.

8. The kit of claim 2, wherein the nucleic acid probe comprises the sequence of SEQ ID NO:

4.

9. The kit of claim 1, wherein the forward primer and/or reverse primer are detectably labeled with a fluorescent dye.

10. The kit of claim 2, wherein the nucleic acid probe is detectably labeled with a fluorescent dye.

11. The kit of claim 1, wherein the forward primer and reverse primer are present together in an amplification master mix that further comprises DNA polymerase, dNTPs and PCR buffer.

12. A kit comprising:

(a) a primer pair comprising

(i) a forward primer that comprises the sequence of SEQ ID NO;

89; and

(ii) a reverse primer that comprises the sequence of SEQ ID NO;

90; and

(b) a detectably labeled nucleic acid probe that that binds to an amplification product produced by the forward primer and the reverse primer.

13. The kit of claim 12, wherein the detectably labeled nucleic acid probe spans a junction site between exons 10 and 6b resulting from a duplication of exon 6b through exon 10 of the CFTR gene.

14. The kit of claim 12, wherein the detectably labeled nucleic acid probe spans a IVS10+2,987/IVS6a+415 junction site.

15. The kit of claim 12, wherein the detectably labeled nucleic acid probe comprises the sequence of SEQ ID NO:

2, 3, or 4.

16. The kit of claim 12, wherein the forward primer, reverse primer, and/or probe are present together in an amplification master mix that further comprises DNA polymerase, dNTPs and PCR buffer.

17. The kit of claim 12, wherein the nucleic acid probe is detectably labeled with a fluorescent dye.

18. The kit of claim 12, wherein the forward primer and/or reverse primer are detectably labeled with a fluorescent dye.